Novelties in obesity pharmacotherapy in 2023

Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription. (c) 2023 Societe francophone nutrition clinique et metabolisme (SFNCM). Published by Elsevier Masson SAS. All rights reserved.